Depresión perimenopáusicauna revisión

  1. Sesma Pardo, Eva
  2. Finkle, Joshua
  3. González Torres, Miguel Ángel
  4. Gaviria, Moisés
Revista:
Revista de la Asociación Española de Neuropsiquiatría

ISSN: 0211-5735

Año de publicación: 2013

Volumen: 33

Número: 120

Páginas: 681-691

Tipo: Artículo

DOI: 10.4321/S0211-57352013000400002 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Revista de la Asociación Española de Neuropsiquiatría

Objetivos de desarrollo sostenible

Resumen

A partir de la adolescencia, las mujeres presentan un riesgo 1,5 a 3 veces mayor que los hombres de padecer un trastorno depresivo. Este riesgo aumenta en el periodo de transición hacia la menopausia o perimenopausia, cuando la vulnerabilidad depresiva se hace especialmente intensa. Se han postulado mecanismos hormonales, psicológicos y socioculturales para entender la etiopatogenia de estos cuadros. El tratamiento de la depresión en la perimenopausia viene determinado por la gravedad clínica e incluye antidepresivos, psicoterapia y, en ocasiones, terapia hormonal sustitutiva mediante estrógenos. La depresión perimenopáusica constituye un problema infradiagnosticado e infratratado, que genera un alto nivel de sufrimiento y que merece una mayor atención por parte de los clínicos y el sistema sanitario

Referencias bibliográficas

  • (1) Avis NE, Stellato R, Crawford S, Bromberger J, Ganz P, Cain V, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 2001;52(3):345- 56.
  • (2) Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates and course of minor depression and major depression in the National Comorbidity Survey. J Affect Disord 1997;45:19-30.
  • (3) Kessler RC. Epidemiology of women and depression. J Affect Disord 2003;74:5-13.
  • (4) Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, 7th edition. 2003, Elsevier.
  • (5) Kato I, Toniolo P, Akhmedkhanov A, Koenig KL, Shore R, Zeleniuch-Jacquotte A (1998). “Prospective study of factors influencing the onset of natural menopause”. J Clin Epidemiol 51(12):1271– 76.
  • (6) Kaufman DL, Slone D, Rosenberg L, Miettinen OS, Shapiro S. Cigarette smoking and age of natural menopause. American Journal of Public Health 1980;70(4):420-22.
  • (7) Mosby’s Medical Dictionary, 8th edition. 2009, Elsevier.
  • (8) Blake J: Menopause: evidence-based practice. Best Pract Res Clin Obstet Gynaecol 2006; 20:799–839.
  • (9) Freeman EW, Samuel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychyatry 2006;63:375- 82.
  • (10) Bosworth HB, Bastian LA, Kuchibhatla MN, Steffens DC, McBride CM, Skinner CS, et al. Depressive symptoms, menopausal status, and climacteric symptoms in women at midlife. Psychosom Med 2001;63:603-8.
  • (11) Gyllstrom ME, Schereiner PJ, Harlow BL. Perimenopause and depression: strength of association, causal mechanisms and treatment recommendations. Best Pract Res Clin Obstet Gynaecol 2007;21:275-92.
  • (12) Burger HG, Dudley EC, Hopper JL et al. Prospectively measured levels of serum FSH, estradiol and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 1999;84:4025-30.
  • (13) Klein NA, Illingworth PJ, Groome NP et al. Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab 1996;81:2742-45.
  • (14) Santoro N. The menopause transition. Am J Med 2005;118(12 Suppl):8S-13S.
  • (15) Rannevik G, Jeppsson S, JohnellOet al. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1995;21:103-13.
  • (16) Stearns V, Ullmer L, Lopez JF et al. Hot flushes. Lancet 2002 Dec;360: 1851-61.
  • (17) Freedman RR. Physiology of hot flushes. Am J Human Biol 2001;13:453-64.
  • (18) Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hotflushes. Am J Obstet Gynecol 1999;181:66-70.
  • (19) Dzaja A, Arber S, Hislop J et al. Women’s sleep in health and disease. J Psychiatr Res 2005 Jan;39(1):55-76.
  • (20) Moe KE. Hot flushes and sleep in women. Sleep Med Rev 2004 Dec;8(6):487-97.
  • (21) Szoeke CE, Cicuttini F, Guthrie J et al. Self-reported arthritis and the menopause. Climacteric 2005 Mar;8(1):49-55.
  • (22) Dennerstein Lorraine, Lehert Philippe, Burger Henry et al. Sexuality. Am J Med 2005;118(12 Suppl):59S-63S.
  • (23) Leiblum Sandra R, Koochaki Patricia E, Rodenberg Cynthia A et al. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women’s International Study of Health and Sexuality (WISHeS). Menopause 2006;13(1):46-56.
  • (24) Kaufert PA, Gilbert P & Tate R. The Manitoba Project: a re-examination of the link between menopause and depression. Maturitas 1992;14:143-55.
  • (25) Woods NF, Mariella A, Mitchell ES. Patterns of depressed mood across the menopausal transition: approaches to studying patterns in longitudinal data. Acta Obstet Gynecol Scand 2002;81:623- 32.
  • (26) Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61(1):62–70.
  • (27) Daly RC, Danaceau MA, Rubinow DR, Schmidt PJ. Concordant restoration of ovarian function and mood in perimenopausal depression. Am J Psychiatry 2003;160:1842-46.
  • (28) Harlow BL, Wise LA, Otto MW, Soares CN, Cohen LS. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry 2003;60(1):29-36.
  • (29) Avis NE, Crawford S, Stellato R, Longcope C. Longitudinal study of hormone levels and depression among women transitioning through menopause. Climacteric 2001;4:243-49.
  • (30) Rannevik G, Jeppsson S, Johnell O. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1995;21:103- 13.
  • (31) Avis NE, Brambilla D, McKinlay SM et al. A longitudinal analysis of the association between menopause and depression: results from the Massachusetts women’s health survey. Ann Epidemiol 1994;4:214-20.
  • (32) Avis NE, Kaufert PA, Lock M, McKinlay SM, Vass K. The evolution of menopausal symptoms. Baillieres Clin Endocrinol Metab 1993 Jan;7(1):17-32.
  • (33) Hershey DA, Henkens K, Van Dalen HP. Aging and financial planning for retirement: interdisciplinary influences viewed through a cross-cultural lens. Int J Aging Hum Dev 2010;70(1):1-38.
  • (34) Kobayashi KM, Funk L. Of the family tree: congruence on filial obligation between older parents and adult children in Japanese Canadian families. Can J Aging 2010 Mar;29(1):85-96.
  • (35) Takagi E, Silverstein M, Crimmins E. Intergenerational coresidence of older adults in Japan: conditions for cultural plasticity. J Gerontol B Psychol Sci Soc Sci 2007 Sep;62(5):330-39.
  • (36) Dennerstein L, Dudley E, Guthrie J. Empty nest or revolving door? A prospective study of women’s quality of life in midlife during the phase of children leaving and re-entering the home. Psychol Med 2002;32:545-50.
  • (37) Guthrie JR, Dennerstein L, Taffe JR. The menopausal transition: a 9-year prospective population-based study. The Melbourne Women’s Midlife Health Project. Climacteric 2004 Dec;7(4):375- 89.
  • (38) Woods NF, Mariella A, Mitchell ES. Patterns of depressed mood across the menopausal transition: approaches to studying patterns in longitudinal data. Acta Obstet Gynecol Scand 2002;81:623- 32.
  • (39) Daly E, Gray A, Barlow D et al. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993 Oct 2;307:836-40.
  • (40) Larroy García C, Gómez-Calcerrada SG. Cognitive-behavioral intervention among women with slight menopausal symptoms: a pilot study. Span J Psychol 2011 May;14(1):344-55.
  • (41) Iglesias García C, Ocio León S, Ortigosa Digón JC, et al. Comparison of the effectiveness of venlafaxine in periand postmenopausal patients with major depressive disorder. Actas Esp Psiquiatr 2010 Nov-Dec;38(6):326-31.
  • (42) Ushiroyama T, Ikeda A, Ueki M. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition. J Med 2004;35(1-6):151- 62.
  • (43) Morrison MF, Kallan MJ, Ten Have Tet al. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled. Biol Psychiatry 2004 Feb 15; 55(4):406-12.
  • (44) Resnick S, Maki P, Rapp S, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 2006, 91(5):1802-10.
  • (45) De Noaves Soares C, Almeida OP, Joffee H et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women. Arch Gen Psychiatry 2001;58:529-34.
  • (46) Schmidt Peter J. Mood, depression, and reproductive hormones in the menopausal transition. Am J Med 2005 December 19; 118 (12 Suppl 2): 54-8.
  • (47) Writing Group for the Women’s Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321.
  • (48) The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
  • (49) Collins JA, Blake JM & Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 2005;11(6):545-60.
  • (50) Craig MC, Murphy DG. Estrogen therapy and Alzheimer’s dementia. Ann N Y Acad Sci 2010 Sep;1205:245-53.
Fuente de los datos: Dialnet